Edgar Gonzalez‐Kozlova
YOU?
Author Swipe
View article: Longitudinal profiling of tumor and immune compartments uncovers patterns of dysregulation and associations with response in multiple myeloma
Longitudinal profiling of tumor and immune compartments uncovers patterns of dysregulation and associations with response in multiple myeloma Open
Multiple myeloma (MM) is a malignancy of clonally expanded plasma cells shaped by complex interactions with the immune microenvironment. To investigate immune correlates of treatment response and disease progression, we conducted multi-omi…
View article: Long-lived IgE plasma cells residing in the spleen contribute to the persistence of allergy 4302
Long-lived IgE plasma cells residing in the spleen contribute to the persistence of allergy 4302 Open
Description IgE mediates allergic reactions due to its ability to bind to high affinity receptors on mast cells inducing degranulation upon crosslinking. IgE production is highly regulated and IgE plasma cells (PC) are rare. Most IgE PC ar…
View article: A single-cell spatial transcriptomic census of human skin anatomy
A single-cell spatial transcriptomic census of human skin anatomy Open
The skin is the largest human organ and a site of significant disease burden, yet its cellular and molecular organization across the body are largely undefined. Here, we construct a spatially-resolved single-cell atlas of 1.2 million cells…
View article: TREM2 macrophages are associated with enhanced response to PD-1 blockade in human hepatocellular carcinoma
TREM2 macrophages are associated with enhanced response to PD-1 blockade in human hepatocellular carcinoma Open
Macrophages are known to dampen tumor immunity. However, identifying druggable targets that modulate these cells to improve existing immunotherapies has been limited by a dearth of studies identifying macrophages that associate with pathol…
View article: Multiparametric cellular and spatial organization in cancer tissue lesions with a streamlined pipeline
Multiparametric cellular and spatial organization in cancer tissue lesions with a streamlined pipeline Open
Multiplex immunostaining analysis remains fragmented, underperforming and labour intensive despite tissue proteomic methodologies achieving ever-increasing marker complexity. Here we propose an open-source, user-guided automated pipeline t…
View article: Phase II basket trial of Dual Anti-CTLA-4 and anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: pancreatic neuroendocrine neoplasm (PNEN) cohort
Phase II basket trial of Dual Anti-CTLA-4 and anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: pancreatic neuroendocrine neoplasm (PNEN) cohort Open
Purpose SWOG S1609 D ual A nti-CTLA-4 and anti-PD-1 blockade in R are T umors (DART) studied the efficacy of ipilimumab combined with nivolumab across multiple rare tumor types. We report the results of the pancreatic neuroendocrine neopla…
View article: Longitudinal multi-omic profiling uncovers immune escape and predictors of response in multiple myeloma
Longitudinal multi-omic profiling uncovers immune escape and predictors of response in multiple myeloma Open
Multiple myeloma (MM) is an incurable malignancy of clonally expanded plasma cells shaped by complex interactions with the immune microenvironment. To investigate immune factors driving treatment response and resistance, we conducted multi…
View article: MARQO pipeline resolves multiparametric cellular and spatial organization in cancer tissue lesions
MARQO pipeline resolves multiparametric cellular and spatial organization in cancer tissue lesions Open
Multiplex immunostaining analysis remains fragmented, underperforming, and labor-intensive despite tissue proteomic methodologies achieving ever-increasing marker complexity. Here we propose an open-source, semi-supervised automated pipeli…
View article: Supplementary Table 2 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma
Supplementary Table 2 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma Open
Experimental data userd in the article including Olink, CyTOF populational frequencies, Serology and TCRseq beta chain.
View article: Figure S2 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma
Figure S2 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma Open
Supplemental Figure 2. Cellular marker dynamics in Hodgkin lymphoma during checkpoint blockade treatment. A. Heatmap showing markers and cell types identified through CyTOF (cytometry using time of flight) that significantly change over ti…
View article: Supplementary Table 1 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma
Supplementary Table 1 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma Open
CyTOF antibody panel details.
View article: Figure S1 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma
Figure S1 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma Open
Supplemental Figure 1. A. Volcano plots showing differentially expressed proteins with P<0.05 between treatments.
View article: Figure S3 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma
Figure S3 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma Open
Supplemental Figure 3. Graphical abstract. Top boxes show a simplified trial design including 3 treatments composed by the combination of BV with I, N and I+N. We investigated the differences between responders and non-responders using sta…
View article: Supplementary Table 3 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma
Supplementary Table 3 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma Open
OS Multivariate analysis showing that markers significant during univariate analysis are not significant during multivariate analysis.
View article: Peripheral Transcriptomics in Acute and Long-Term Kidney Dysfunction in SARS-CoV-2 Infection
Peripheral Transcriptomics in Acute and Long-Term Kidney Dysfunction in SARS-CoV-2 Infection Open
Key Points AKI in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is linked to mitochondrial dysfunction and cellular stress, highlighting novel biomarkers for severe AKI. Molecular similarities between AKI in SARS-C…
View article: Immunological biomarkers of response and resistance to treatment with cabozantinib and nivolumab in recurrent endometrial cancer
Immunological biomarkers of response and resistance to treatment with cabozantinib and nivolumab in recurrent endometrial cancer Open
Background Antiangiogenics combined with immune checkpoint blockade have become standard of care for recurrent endometrial cancer after standard platinum-based chemotherapy. To dissect mechanisms and define biomarkers associated with clini…
View article: Dendritic cells type 1 control the formation, maintenance, and function of tertiary lymphoid structures in cancer
Dendritic cells type 1 control the formation, maintenance, and function of tertiary lymphoid structures in cancer Open
Tertiary lymphoid structures (TLS) are organized immune cell aggregates that arise in chronic inflammatory conditions. In cancer, TLS are associated with better prognosis and enhanced response to immunotherapy, making these structures attr…
View article: Baseline colitogenicity and acute perturbations of gut microbiota in immunotherapy-related colitis
Baseline colitogenicity and acute perturbations of gut microbiota in immunotherapy-related colitis Open
Immunotherapy-related colitis (irC) frequently emerges as an immune-related adverse event during immune checkpoint inhibitor therapy and is presumably influenced by the gut microbiota. We longitudinally studied microbiomes from 38 ICI-trea…
View article: Extracellular vesicles, RNA sequencing, and bioinformatic analyses: Challenges, solutions, and recommendations
Extracellular vesicles, RNA sequencing, and bioinformatic analyses: Challenges, solutions, and recommendations Open
Extracellular vesicles (EVs) are heterogeneous entities secreted by cells into their microenvironment and systemic circulation. Circulating EVs carry functional small RNAs and other molecular footprints from their cell of origin, and thus …
View article: Immune Profiling Reveals Distinct Features of Multiple Myeloma Subtypes Defined By Multi-Omics Network Analysis
Immune Profiling Reveals Distinct Features of Multiple Myeloma Subtypes Defined By Multi-Omics Network Analysis Open
Introduction: Multiple myeloma (MM) has a highly heterogeneous genomic landscape, challenging patient stratification and clinical management. By combining bulk tumor profiling with single-cell data of the tumor microenvironment (TME), we a…
View article: Ten challenges and opportunities in computational immuno-oncology
Ten challenges and opportunities in computational immuno-oncology Open
Immuno-oncology has transformed the treatment of cancer, with several immunotherapies becoming the standard treatment across histologies. Despite these advancements, the majority of patients do not experience durable clinical benefits, hig…
View article: Supplementary Table 2 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma
Supplementary Table 2 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma Open
Experimental data userd in the article including Olink, CyTOF populational frequencies, Serology and TCRseq beta chain.
View article: Figure S1 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma
Figure S1 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma Open
Supplemental Figure 1. A. Volcano plots showing differentially expressed proteins with P<0.05 between treatments.
View article: Figure S3 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma
Figure S3 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma Open
Supplemental Figure 3. Graphical abstract. Top boxes show a simplified trial design including 3 treatments composed by the combination of BV with I, N and I+N. We investigated the differences between responders and non-responders using sta…
View article: Figure S1 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma
Figure S1 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma Open
Supplemental Figure 1. A. Volcano plots showing differentially expressed proteins with P<0.05 between treatments.
View article: Figure S2 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma
Figure S2 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma Open
Supplemental Figure 2. Cellular marker dynamics in Hodgkin lymphoma during checkpoint blockade treatment. A. Heatmap showing markers and cell types identified through CyTOF (cytometry using time of flight) that significantly change over ti…
View article: Figure S3 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma
Figure S3 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma Open
Supplemental Figure 3. Graphical abstract. Top boxes show a simplified trial design including 3 treatments composed by the combination of BV with I, N and I+N. We investigated the differences between responders and non-responders using sta…
View article: Supplementary Table 2 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma
Supplementary Table 2 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma Open
Experimental data userd in the article including Olink, CyTOF populational frequencies, Serology and TCRseq beta chain.